Company intelligence / Profile preview
Intratus
San Diego, California, United Statesintratus.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Intratus has developed a proprietary, non-invasive, sustained-release cream-based transdermal drug delivery platform for ophthalmic diseases; key programs are in pre-clinical or early clinical assessment, with one platform licensed to Glaukos for glaucoma and corneal disorders.
- Therapeutic areas
- CardiovascularOphthalmology
- Modalities
- Small moleculeBiologicDrug delivery platform
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Glaukos (global licensing for ophthalmic drug delivery platform - glaucoma and corneal disorders)
Beyond the preview
Go deeper on Intratus.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intratus.